Alymsys Injection, Solution
Product Images NDC 85006-1755

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Alymsys (NDC 85006-1755). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Valorum Biologics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alymsys Bevacizumab Maly Injection 1)

A survival curve graph showing the proportion of patients surviving over a duration of up to 30 months. The graph compares two groups: one receiving IFL + Placebo (red line) and the other receiving IFL + Bevacizumab (blue line). The x-axis represents duration of survival in months and the y-axis represents the proportion surviving. Patient counts at risk are listed at various time points for both groups.*

FDA Label Image

Valorum-400mg Carton (Alymsys Bevacizumab Maly Injection 10)

Carton label for Alymsys (bevacizumab-maly) injection, 400 mg/16 mL (25 mg/mL) for intravenous infusion after dilution. The label indicates a single-dose 16 mL vial with instructions to discard unused portions. Manufactured by Amneal Pharmaceuticals LLC and distributed by Valorum Biologics, LLC, with storage instructions and ingredient details included.*

FDA Label Image

Figure 2 (Alymsys Bevacizumab Maly Injection 2)

A survival curve chart displaying the proportion surviving over study months comparing two treatments: chemotherapy alone (dashed blue line) and chemotherapy plus Bevacizumab (solid red line). The x-axis represents study months from 0 to 48, and the y-axis represents the proportion surviving from 0 to 1. Below the graph, numbers at risk at various months for each treatment group are shown.*

FDA Label Image

Figure 3 (Alymsys Bevacizumab Maly Injection 3)

A survival curve chart comparing the proportion surviving over time (in months) between two groups: one treated with PC (blue line, n=444) and the other treated with PC plus Bevacizumab (red line, n=434). The chart also includes a table below indicating the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 4 (Alymsys Bevacizumab Maly Injection 4)

A Kaplan-Meier survival curve graph displaying progression-free survival over 24 months for two patient groups. The y-axis shows proportion progression-free, and the x-axis shows time in months. One curve (blue) represents patients treated with Bevacizumab plus IFN-alfa, while the other (red) shows placebo plus IFN-alfa. Patient numbers at risk are provided at various time points below the x-axis.*

FDA Label Image

Figure 5 (Alymsys Bevacizumab Maly Injection 5)

A Kaplan-Meier survival curve chart depicting the proportion of overall survival over time (months). The chart compares two groups: one treated with chemotherapy alone and another with chemotherapy plus bevacizumab, showing survival probabilities with time. The graph includes a number-at-risk table below the time axis for each group at various time points.*

FDA Label Image

Figure 6 (Alymsys Bevacizumab Maly Injection 6)

Kaplan-Meier curve depicting progression-free survival proportions over time in months for ALYMSYS (bevacizumab-maly) patient groups with varying C-reactive protein (CRP) levels: CRP <5 (blue), CRP ≥5 (red), and CRP ≥5a (green). The chart includes number of patients at risk below the x-axis.*

FDA Label Image

Valorum-100mg Label (Alymsys Bevacizumab Maly Injection 7)

ALYMSYS 100 mg/4 mL (25 mg/mL) injection solution label for intravenous infusion after dilution. The label states it is a 4 mL single-dose vial with no preservatives. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F) and protection from light. Dosage information directs to see prescribing info. It is distributed by Valorum Biologics, LLC with Lot and Expiration date fields present but not filled.*

FDA Label Image

Valorum-100mg Carton (Alymsys Bevacizumab Maly Injection 8)

Packaging label for Alymsys (bevacizumab-maly) injection, 100 mg/4 mL (25 mg/mL) single-dose vial for intravenous infusion. The label displays the product name, strength, dosage form, and instructions for use after dilution. It includes manufacturing information from Amneal Pharmaceuticals LLC and distribution by Valorum Biologics, LLC, with storage and handling instructions and a barcode.*

FDA Label Image

Valorum-400mg Label (Alymsys Bevacizumab Maly Injection 9)

Label for ALYMSYS (bevacizumab-maly) injection, solution, 400 mg/16 mL (25 mg/mL) for intravenous infusion after dilution. The label specifies storage refrigerated at 2°C to 8°C and notes no preservatives. It is a single-dose vial with instructions to discard unused portion. Distributed by Valorum Biologics, LLC, New York, NY.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.